Fate Therapeutics, Inc. (FATE) is a Biotechnology company in the Healthcare sector, currently trading at $1.34. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is FATE = $40 (+2847.8% upside).
Valuation: FATE trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.2.
Financials: revenue is $7M, -54.6%/yr average growth. Net income is $136M (loss), growing at +16%/yr. Net profit margin is -2051.1% (negative). Gross margin is -94.1% (-179.8 pp trend).
Balance sheet: total debt is $78M against $207M equity (Debt-to-Equity (D/E) ratio 0.38, conservative). Current ratio is 5.79 (strong liquidity). Debt-to-assets is 24.4%. Total assets: $319M.
Analyst outlook: 16 / 31 analysts rate FATE as buy (52%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
